TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NOTE: the following eligibility criteria were applicable to acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) patients for the Phase 1 portion of this study, and to ALL patients for the Phase 2 portion of the study (only ALL patients were allowed in the Phase 2 portion of the study).~* ALL with \> 25% blasts in bone marrow; AML with ≥ 5% blasts in bone marrow; ALL and AML patients may have extramedullary disease~* Karnofsky Performance Status ≥ 50 for patients \> 10 years old; Lansky Performance Status ≥ 50 for patients ≤ 10 years old~* Prior therapy: AML: 1-2 prior induction regimens and ≤ 1 hematopoietic stem cell transplant (HSCT); ALL: 1-3 prior induction regimens~* Adequate liver, renal, pancreatic, and cardiac function~* Have received no prior HSCT (study amended in Phase 2 to exclude patients with prior HSCT)~Exclusion Criteria:~* NOTE: the following eligibility criteria were applicable to ALL and AML patients for the Phase 1 portion of this study, and to ALL patients for the Phase 2 portion of the study (only ALL patients were allowed in the Phase 2 portion of the study).~* Burkitt's leukemia~* Previous treatment with clofarabine~* Uncontrolled systemic fungal, bacterial or other infection and 48 hrs negative blood cultures required for patients with a history of fever within 3 days of enrollment~* Active CNS involvement (i.e., should be CNS1 or CNS2)~* Inadequate time since last therapy: ≤ 14 days since last cytotoxic chemotherapy; ≤ 7 days since last biologic therapy; ≤ 14 days since last monoclonal antibody therapy~* Have received prior HSCT (study amended in Phase 2 to exclude patients with prior HSCT)~* Pregnant or lactating~* Have tested positive for hepatitis B or hepatitis C infection or history of cirrhosis

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- clofarabine, etoposide, cyclophosphamide (Type: EXPERIMENTAL): Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m\^2, etoposide dosage from 75-100 mg/m\^2, cyclophosphamide dosage from 340-440 mg/m\^2.~Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide 440 mg/m\^2 delivered intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Challenge Dose in Adults (V232-059-10)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In general good health based on a medical history.~* Received 3 doses of an Hepatitis B vaccine in Base Study V232-059, NCT00440531 at least 2 years prior to enrollment in this study.~Exclusion Criteria:~* Known history of previous Hepatitis B infection.~* History of vaccination with any Hepatitis B vaccine within the last 2 years.~* History of febrile illness.~* Known or suspected hypersensitivity to any component of HBVaxPro.~* Receipt of medication / vaccine that may interfere with study assessments.~* Known or suspected immune impairment.~* Pregnant women and nursing mothers.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Modified Process Hepatitis B Vaccine in Base Study (Type: EXPERIMENTAL): Participants who received 3 doses of Modified Process Hepatitis B Vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
- ENGERIX-B™ Vaccine in Base Study (Type: EXPERIMENTAL): Participants who received 3 doses of ENGERIX-B™ vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria~1. Women with medically indicated IVF or ICSI using her own oocytes.~2. GnRH antagonist protocol, a single injection of hCG for triggering final follicular maturation and luteal phase support with vaginal micronized progesterone.~3. Evidence of uterine contractions by transvaginal ultrasound at baseline.~Key Exclusion Criteria~1. Blastocyst stage or frozen-thaw transfers~2. Clinically significant abnormalities in ECG, vital signs, physical examination or clinical laboratory results~3. Severe endometriosis and/or adenomyosis or risk of ovarian hyper stimulation syndrome

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- OBE001 dose 1 (Type: EXPERIMENTAL): None
- OBE001 dose 2 (Type: EXPERIMENTAL): None
- OBE001 dose 3 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fructose Consumption and Metabolic Dysregulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index 27-40~* Waist \> 96 cm~* Age 20-60 years~* Male~Exclusion Criteria:~* Smoking~* Active health problems~* Contraindications to MRI scanning~* Bleeding tendency~* Abnormal liver or renal function tests~* Type 2 diabetes~* Evidence of metabolic or viral liver disease~* Alcohol intake \> 21 units per week~* Chronic medication except ones needed for stable hypertension

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- After fructose feeding (Type: EXPERIMENTAL): After 3 month fructose diet 75 g/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Registration Trial in China Humalog Mix 50

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men and women who have had either type 1 or type 2 diabetes (World Health Organization\[WHO\]classification)for at least 2 months and are between the ages of 18 and 70 (inclusive) at the signing of the informed consent.~2. Have been treated with commercially available human insulin mix 50/50 or human insulin mix 30/70 twice daily as the only pharmacological treatment for their diabetes for at least 2 months prior to entering the study.~3. Have an HbA1c between 1.1 and 1.7 times the upper limit of the normal reference rang(inclusive) as determined by a local laboratory within 2 weeks prior to or at Visit 1.~4. Have achieved compliance with their diets and insulin therapies as determined by the investigators and perform regular blood glucose monitoring.~5. Have given informed consent to participate in this study in accordance with local regulations.~Exclusion Criteria:~{1\] Have used oral antidiabetic agents, including biguanides, sulfonylureas, glucosidase inhibitors, and insulin-sensitivity enhancers within 30 days prior to entry into the study.~\[2\] Receive a total daily dose of insulin \>2 units/kg.~\[3\] Have had more than two episodes of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to entry into the study.~\[4\] Have a body mass index \>35 kg/m2.~\[5\] Have serum creatinine \> the upper limit of normal (ULN), as determined by a local laboratory.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protecting Our Community: COVID-19 Testing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* Member of study community~* No current significant symptoms consistent with COVID-19~Exclusion Criteria:~* \< 18 years old~* Not a member of the study community~* Current significant symptoms consistent with COVID-19

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active delivery (Type: EXPERIMENTAL): For the participants randomized to the active arm will have their home collection kit registered on their behalf by bilingual (Spanish and English) community health workers, who are trusted community members. Home testing kits augmented with study developed materials will direct participants to contact the study team for assistance.
- Passive delivery (Type: EXPERIMENTAL): Participants randomized to the passive arm will receive a home test kit augmented with instructions on how to self-register their kit online, and will be directed to contact Everlywell for assistance, if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heavy/hazardous drinking levels (i.e., consuming 8 or more drinks per week, or have reported at least two heavy drinking occasions \[4 or more drinks/drinking episode\] in the last six months, or score positively on the CAGE or T-ACE).~* HIV-positive~* Receiving HIV care in Johns Hopkins Hospital (JHH) Moore Clinic~Exclusion Criteria:~* Actively psychotic and other severe mental health symptoms~* Current enrollment in alcohol or drug treatment~* Current enrollment in Hopkins psychiatric services~* Pregnancy (because of the ethical concern of randomization to standard care)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Brief Intervention (Type: EXPERIMENTAL): The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
- 2 Standard Care Arm (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged at least 13 years~* Signed written informed consent~* Clear clinical and laboratory diagnosis of HAE with baseline plasma level of functional C1INH of less than 50% of normal~* Willingness and ability to comply with all protocol procedures~* Clinical symptoms of an eligible HAE attack with onset less than 5 hours before the time of initial evaluation~Exclusion Criteria:~* Medical history of allergy to rabbits or rabbit-derived products (including rhC1INH), or positive anti-rabbit dander IgE test (cut off \>0.35 kU/L; ImmunoCap® assay; Phadia or equivalent).~* A diagnosis of acquired C1INH deficiency (AAE)~* Pregnancy, or breastfeeding, or current intention to become pregnant~* Treatment with any investigational drug in the past 30 days~* Known or suspected addiction to drug and/or alcohol abuse~* Suspicion for an alternate explanation of the symptoms other than acute HAE attack

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhC1INH (Type: EXPERIMENTAL): None
- Placebo (Saline) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* BMI 20-45kg/m2 inclusive~Exclusion Criteria:~* females who are pregnant, lactating or \<6 weeks post-partum~* current symptomatic heart failure (NYHA Class III or IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albiglutide + metformin (Type: EXPERIMENTAL): Albiglutide + metformin + placebo sitagliptin + placebo glimepiride
- sitagliptin + metformin (Type: ACTIVE_COMPARATOR): Sitagliptin + metformin + placebo albiglutide + placebo glimepiride
- glimepiride + metformin (Type: ACTIVE_COMPARATOR): Glimepiride + metformin + placebo albiglutide + placebo sitagliptin
- metformin + placebo (Type: ACTIVE_COMPARATOR): Metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 12 years of age and older with 2-year history of allergic conjunctivitis~Exclusion Criteria:~* No active ocular or nasal infection

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bepotastine Besilate Ophthalmic Solution (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Different Bone Grafts in Accelerating Tooth Movement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A moderate 4-5mm crowding of the lower anterior teeth~* Good oral hygiene~* Healthy systemic condition~Exclusion Criteria:~* previous orthodontic treatment~* Probing depth values exceeding 3 mm~* Radiographic evidence of bone loss~* Regular administration medication that affects bone metabolism such as prolonged use of corticosteroids, or bisphosphonates and NSAIDs.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Corticotomy alone (Type: NO_INTERVENTION): Group I will be treated with a modified technique of corticotomy assisted orthodontic treatment (CAOT) alone
- Corticotomy + xenograft (Type: EXPERIMENTAL): group II (included 6 females and 5 males) that treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
- Corticotomy + bioactive glass (Type: EXPERIMENTAL): group III (included 7 females and 4 males) that treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triple Combination Therapy in High Risk Crohn's Disease (CD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Has an initial diagnosis of CD established within 24 months prior to screening with involvement of the ileum and/or colon that can be assessed by ileocolonoscopy.~2. Has moderate to severely active CD during Screening defined by a centrally assessed simple endoscopic score for Crohn disease (SES-CD) score \>=7 (or \>=4 if isolated ileal disease).~Exclusion Criteria:~Gastrointestinal (GI) Exclusion Criteria~1. Has a diagnosis of ulcerative colitis (UC) or indeterminate colitis.~2. Has clinical evidence of a current abdominal abscess or a history of prior abdominal abscess.~3. Has a known perianal fistula with abscess. (The participant may have a perianal fistula without abscess.)~4. Has a known fistula (other than perianal fistula).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) (Type: EXPERIMENTAL): In Triple Combination Therapy Phase, vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2, 6, 14 and 22, with adalimumab 160 mg subcutaneously (SC), once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34. In Monotherapy Phase, vedolizumab 300 mg IV infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~The inclusion criteria for the study are broad reflecting the target population that would eventually receive an efficacious vaccine.~* Informed consent~* Age greater than or equal to 18 years~* Likely to be in the surrounding area of the vaccination center for at least one year.~EXCLUSION CRITERIA:~* Fever greater than or equal to 38.0 degrees Celsius~* History of EVD (self-report)~* Current pregnancy (a negative urine pregnancy test is required for women of child-bearing potential)~* Breast-feeding an infant~* Any condition which would limit the ability of the participant to meet the requirements of the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2 (Type: EXPERIMENTAL): ChAd3-EBO Z
- 3 (Type: EXPERIMENTAL): VSVG-ZEBOV
- 1 (Type: PLACEBO_COMPARATOR): Placebo (Saline)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, age 21 to 65 years inclusive~2. Diagnosis of narcolepsy per International Classification of Sleep Disorders (ICSD-3) or Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5)~3. BMI 18 to \<40 kg/m2~4. Willing and able to provide written informed consent~Exclusion Criteria:~1. Female subjects who are pregnant, nursing, or lactating~2. Moderate or severe sleep apnea~3. Any other clinically relevant medical, behavioral, or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness~4. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria~5. History or presence of any unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy and/or safety assessments per the judgment of the investigator~6. History of bariatric surgery within the past year or a history of any gastric bypass procedure~7. Presence or history of significant cardiovascular disease~8. Unable to washout or refrain from taking any over-the-counter (OTC) or prescription medications that could affect sleep-wake function

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Once daily dosing
- JZP-110 (Type: ACTIVE_COMPARATOR): 150 mg/day for first 3 days and 300 mg/day for next 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete